WallStreetZenWallStreetZen

NASDAQ: GANX
Gain Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GANX

Based on 1 analyst offering 12 month price targets for Gain Therapeutics Inc

Min Forecast
$8.00+349.44%
Avg Forecast
$8.00+349.44%
Max Forecast
$8.00+349.44%

Should I buy or sell GANX stock?

Based on 1 analyst offering ratings for Gain Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although GANX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates GANX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their GANX stock forecasts and price targets.

GANX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-19

1 of 1

Forecast return on equity

Is GANX forecast to generate an efficient return?

Company
-108.71%
Industry
74.01%
Market
170.14%
GANX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GANX forecast to generate an efficient return on assets?

Company
-81.26%
Industry
29.14%
GANX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GANX earnings per share forecast

What is GANX's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.62
Avg 2 year Forecast
-$0.65
Avg 3 year Forecast
-$0.83

GANX revenue forecast

What is GANX's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

GANX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GANX$1.78$8.00+349.44%Buy
RLYB$14.35N/AN/A
TCRX$1.16$5.00+331.03%Buy
ICCC$8.36N/AN/A
XBIT$2.50N/AN/A
View Top Biotech Stocks

Gain Therapeutics Stock Forecast FAQ

Is Gain Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: GANX) stock is to Buy GANX stock.

Out of 1 analyst, 0 (0%) are recommending GANX as a Strong Buy, 1 (100%) are recommending GANX as a Buy, 0 (0%) are recommending GANX as a Hold, 0 (0%) are recommending GANX as a Sell, and 0 (0%) are recommending GANX as a Strong Sell.

If you're new to stock investing, here's how to buy Gain Therapeutics stock.

What is GANX's earnings growth forecast for 2026-2028?

(NASDAQ: GANX) Gain Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.

Gain Therapeutics's earnings in 2026 is -$21,239,773.On average, 7 Wall Street analysts forecast GANX's earnings for 2026 to be -$26,445,504, with the lowest GANX earnings forecast at -$33,022,756, and the highest GANX earnings forecast at -$22,393,370. On average, 6 Wall Street analysts forecast GANX's earnings for 2027 to be -$27,746,452, with the lowest GANX earnings forecast at -$30,975,362, and the highest GANX earnings forecast at -$21,049,768.

In 2028, GANX is forecast to generate -$35,458,302 in earnings, with the lowest earnings forecast at -$39,710,909 and the highest earnings forecast at -$30,454,983.

What is GANX's revenue growth forecast for 2026-2028?

(NASDAQ: GANX) Gain Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.12%.

Gain Therapeutics's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast GANX's revenue for 2026 to be $0, with the lowest GANX revenue forecast at $0, and the highest GANX revenue forecast at $0. On average, 6 Wall Street analysts forecast GANX's revenue for 2027 to be $0, with the lowest GANX revenue forecast at $0, and the highest GANX revenue forecast at $0.

In 2028, GANX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is GANX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: GANX) forecast ROA is -81.26%, which is lower than the forecast US Biotechnology industry average of 29.14%.

What is GANX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year GANX price target, the average GANX price target is $8.00, with the highest GANX stock price forecast at $8.00 and the lowest GANX stock price forecast at $8.00.

The Wall Street analyst predicted that Gain Therapeutics's share price could reach $8.00 by Dec 19, 2026. The average Gain Therapeutics stock price prediction forecasts a potential upside of 349.44% from the current GANX share price of $1.78.

What is GANX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: GANX) Gain Therapeutics's current Earnings Per Share (EPS) is -$0.58. On average, analysts forecast that GANX's EPS will be -$0.62 for 2026, with the lowest EPS forecast at -$0.77, and the highest EPS forecast at -$0.53. On average, analysts forecast that GANX's EPS will be -$0.65 for 2027, with the lowest EPS forecast at -$0.73, and the highest EPS forecast at -$0.49. In 2028, GANX's EPS is forecast to hit -$0.83 (min: -$0.93, max: -$0.71).

What is GANX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: GANX) forecast ROE is -108.71%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.